相关实验视频

Updated: Sep 16, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

脏缩可以增加心房动中的节律控制吗?

Azka Naeem¹, Vartika Singh², Mohammad Hamza³

¹From the Department of Internal Medicine, Maimonides Medical Centre, Brooklyn, NY.

Cardiology in review

|July 7, 2025

概括

结合脏缩 (RDN) 与肺静脉隔离 (PVI) 来治疗心房动 (AF) 并没有改善AF复发率. 然而,这种组合显著降低了心律失常负担,主要心脏不良事件和左心房直径.

科学领域:

心脏病学心脏病学
电子生理学电子生理学
干预心脏病学干预心脏病学

背景情况:

肺静脉隔离 (PVI) 是对心房 (AF) 的标准治疗方法,但长期的成功率可能不够理想.
脏缩 (RDN) 是一种新兴的治疗方法,其向的是同情神经系统.

研究的目的:

评估结合肺静脉隔离 (PVI) 与肺静脉隔离 (PVI) 结合治疗心房动 (AF) 的疗效,与单独使用PVI相比.
评估RDN + PVI对AF复发,疾病负担和安全结果的影响.

主要方法:

一项对8项随机对照试验 (RCT) 的元分析,比较了AF患者的RDN + PVI与单独的PVI.
在 MEDLINE,Embase 和 Clinicaltrials.gov.gov 的系统文献搜索.
使用Comprehensive R档案网络软件与Mantle-Haenszel随机效应模型进行数据分析.

主要成果:

在AF复发 (RR,0.75;P = 0.1212),非AF复发 (RR,1.25;P = 0.2235) 或停用抗心律失常药物 (RR,1.85;P = 0.0864) 之间没有显著差异.
在RDN + PVI组中,心律失常负担 (SMD,-1.17; P = 0.0271),主要不良心脏事件 (RR,0.33; P = 0.0029) 和左心房直径 (SMD,-3.22; P = 0.0372) 显著减少.
在全因死亡率,中风,出血或手术并发症方面没有显著差异.

结论:

与肺静脉隔离相结合的病变并不能显著改善AF复发率或与单独PVI相比没有AF率.
组合疗法在减少整体心律失常负担,主要心脏不良事件和左心房大小方面表现有前途.
需要进一步的研究来澄清RDN在AF管理中的作用.

关键词:

抗心律失常药物抗心律失常药物节律失常负担的负担是心律失常.心房动是心房动的一种.心房动的复发心房动的复发肺静脉隔离肺静脉隔离肺静脉隔离脏变质是指脏的变质.

更多相关视频

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Disturbances in Heart Rhythm

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...